Navigation Links
Insight into mechanisms of diabetes-induced microvascular disease reveals new therapies
Date:7/16/2008

New findings from Bristol scientists could lead to future treatments to prevent lower limb amputations in diabetes - which currently affect 100 people a week in the UK (source Diabetes UK).

The research from the University of Bristol is published online in Circulation Research and was funded by the British Heart Foundation (BHF) and the European Vascular Genomic Network of Excellence (EVGN).

Diabetes can have serious complications like gangrene and skin ulcers due to a restriction of blood supply to and healing capacity of the affected areas and this causes the dysfunction of cells lining the blood vessels. Legs and feet are often severely affected, and, after blood supply is obstructed or injury, the tissue seems to be unable to heal itself by growing new blood vessels making the situation much worse. If gangrenous wounds fail to heal amputation may be the only option.

Dr Costanza Emanueli, BHF Reader at Bristol University and colleagues at the Bristol Heart Institute have previously found that a group of growth factors - known as neurotrophins - play a role in the vascular system. Growth factors act on two completely different types of cellular receptors. One type, trk, mediates positive actions, such as survival and growing new blood vessels and the other, p75NTR, has not been comprehensively characterised.

In healthy blood vessels, the cells that line the blood vessels do not possess the p75NTR receptor, and the development of new blood vessels and healing of the obstructed blood supply and wounds is rapid. However, diabetes causes the cells lining the blood vessels to produce the p75NTR receptor, and prevents the growth of new blood vessels necessary for blood supply and healing of damaged tissue.

Dr Emanueli's group found that if they put the receptor gene into healthy blood vessel cells, the cells became dysfunctional. Equally, injecting the gene into healthy muscle and then restricting blood supply caused impaired healing following the injury identical to that seen in diabetes.

The final proof was to inhibit the p75NTR receptor in diabetic mice before restricting the blood supply to one of their "limbs". The researchers found that p75NTR inhibition enabled the limb to recover from the restricted blood flow and be well supplied with blood.

p75NTR acts by depressing the cell's normal signalling mechanisms that are necessary to stimulate the growth of new blood vessels. In its absence, this process proceeds normally.

Dr Emanueli said: "Our findings demonstrate the importance of understanding the individual factors responsible for such diabetes-induced complications. The data reveal that by suppressing the action of one particular gene, we can improve recovery of tissues following inadequate blood flow, and this opens up new avenues for its use to combat diabetes-induced vascular disease."


'/>"/>

Contact: joanne.fryer@bristol.ac.uk
joanne.fryer@bristol.ac.uk
44-117-331-7276
University of Bristol
Source:Eurekalert

Related medicine news :

1. Pitt-led research provides insight into development of congenital circulatory defects
2. MedInsights, Inc. Selects Douglas Young as VP - Sales & Product Development
3. Bacterial peptide provides new insight into common tumor suppressor
4. Circulating Tumor Cells Reveal Insights Into Lung Cancers
5. Leaders Develop Leaders: Insights from Global Benchmarking Councils 10th Annual Human Resources Conference
6. CVS Caremark to Present Insights on Redefining the Consumer Health Care Experience at AHIP Institute 2008
7. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
8. New molecular insight into amboebic dysentery
9. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
10. New insight into RA patient priorities and motivators for clinical trial involvement
11. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... 29, 2016 , ... For those who skip meals occasionally (which is pretty ... among the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya ... Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley Jr., ... episode, airing third quarter 2016 via Discovery Channel. Dates and show times TBA. ... Products, located in Greenwood, Wisconsin applies product research and development and continuous technological ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media Group ... patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci ... Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated their ...
(Date:4/29/2016)... Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... week long softball camp from July 24th – 27th for girls aged 10-18. All ... camp is held at the beautiful Clark V. Whited Complex, one of the finest ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
Breaking Medicine Technology: